Arrowhead Pharmaceuticals Inc (ARWR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $67.13 (-0.90%), Market cap $10.64B, 52-week low–high $14.71 ~ $79.69.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clin
Financial statements, price targets, institutional (13F) holdings and related news for Arrowhead Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Arrowhead Pharmaceuticals Inc trades at $67.13 (-0.90%). Real-time quotes and charts are available on BlackAll Trade.
Arrowhead Pharmaceuticals Inc has a market cap of about $10.64B.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phas